What question did this study set out to answer?

This research aims to evaluate the clinical efficacy, safety, and drug sustainability after switching from originator ustekinumab to its biosimilar in IBD patients.

January 23, 2026Journal of Crohn s and Colitis

P0730Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in Inflammatory Bowel Disease

View Full Paper

Ask AI

Bookmark

This research aims to evaluate the clinical efficacy, safety, and drug sustainability after switching from originator ustekinumab to its biosimilar in IBD patients.
Included 81 IBD patients, predominantly with Crohn's disease.
Evaluated drug sustainability and biomarker activity at 12 and 24 weeks post-switch.
Collected data on clinical remission rates, adverse events, and previous biological therapy exposure.
Drug sustainability reached 96.3% at 12 weeks and 95% at 24 weeks.
Discontinuation rate was found to be 4.9%.
No significant differences observed in remission rates or biomarker changes pre and post-switch.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational study evaluates drug sustainability and clinical outcomes in IBD after biosimilar switch, suggesting stable efficacy.

Cite This Study

Kritzinger et al. (2026) studied this question.

synapsesocial.com/papers/69730f18c8125b09b0d1eeae https://doi.org/10.1093/ecco-jcc/jjaf231.911

View Full Paper

Ask AI

Bookmark

P0730Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in Inflammatory Bowel Disease

Key Points

Discussion

Implication

Cite This Study

P0730Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in Inflammatory Bowel Disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider